Suppr超能文献

生长分化因子15作为ST段抬高型心肌梗死患者无复流现象的预测指标

Growth Differentiation Factor 15 as a Predictor of the No-Reflow Phenomenon in Patients with ST-Segment Elevation Myocardial Infarction.

作者信息

Kożuch Marcin, Południewski Maciej, Dąbrowski Emil Julian, Tarasiuk Ewa, Dobrzycki Sławomir

机构信息

Department of Invasive Cardiology, Medical University of Bialystok, 24A Sklodowskiej-Curie St., 15-276 Bialystok, Poland.

Department of Cardiology, Medical University of Bialystok, 24A Sklodowskiej-Curie St., 15-276 Bialystok, Poland.

出版信息

J Clin Med. 2022 Dec 29;12(1):245. doi: 10.3390/jcm12010245.

Abstract

Growth differentiation factor 15 (GDF-15) and the no-reflow phenomenon are predictors of mortality after ST-segment elevation myocardial infarction (STEMI). We aimed to assess the relation between GDF-15 concentration on admission and the no-reflow phenomenon. The study was conducted prospectively among 80 consecutive STEMI patients who underwent primary PCI. No-reflow was defined as a corrected TIMI frame count > 27 and myocardial blush grade < 3 after PCI. GDF-15 was measured on admission. We assessed long-term (1.3 years) total mortality and the risk factors of no-reflow. The mean age was 65 (SD 12) years. Mortality rates were 2.5% and 7.5% for in-hospital and long-term observations, respectively. No-reflow occurred in 24% of patients. A negative correlation between TIMI flow after PCI and GDF-15 concentration (R = −0.2540, p = 0.023) was found. Receiver operating characteristic (ROC) analysis revealed GDF-15 as a predictor of no-reflow (AUC-0.698, 95%CI-0.552−0.843, p < 0.05). The multivariate logistic regression analysis revealed that the risk factors for no-reflow occurrence were higher age, a concentration of GDF-15 > 1503 pg/mL, lower systolic blood pressure, and higher troponin I concentration on admission. A higher concentration of GDF-15 can be used as an additional marker of ischemia/reoxygenation injury, subsequent no-reflow phenomenon, and worse long-term outcomes in patients with STEMI.

摘要

生长分化因子15(GDF - 15)与无复流现象是ST段抬高型心肌梗死(STEMI)后死亡率的预测指标。我们旨在评估入院时GDF - 15浓度与无复流现象之间的关系。本研究对80例连续接受直接经皮冠状动脉介入治疗(PCI)的STEMI患者进行了前瞻性研究。无复流定义为PCI术后校正的心肌梗死溶栓治疗(TIMI)帧数>27且心肌灌注分级<3级。入院时测定GDF - 15。我们评估了长期(1.3年)全因死亡率及无复流的危险因素。平均年龄为65(标准差12)岁。住院期间和长期观察的死亡率分别为2.5%和7.5%。24%的患者发生无复流。发现PCI术后TIMI血流与GDF - 15浓度呈负相关(R = -0.2540,p = 0.023)。受试者工作特征(ROC)分析显示GDF - 15是无复流的预测指标(曲线下面积[AUC]-0.698,95%可信区间[CI]-0.552 - 0.843,p < 0.05)。多因素逻辑回归分析显示,无复流发生的危险因素为年龄较大、入院时GDF - 15浓度>1503 pg/mL、收缩压较低及肌钙蛋白I浓度较高。较高的GDF - 15浓度可作为STEMI患者缺血/再灌注损伤、随后的无复流现象及较差长期预后的附加标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6183/9821761/dd54da1be643/jcm-12-00245-g001.jpg

相似文献

3
Predictors of no-reflow phenomenon following percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Ann Cardiol Angeiol (Paris). 2021 Jun;70(3):136-142. doi: 10.1016/j.ancard.2021.04.004. Epub 2021 May 4.

本文引用的文献

1
Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis.
Eur Heart J. 2023 Jan 21;44(4):293-300. doi: 10.1093/eurheartj/ehac577.
5
Management of No-Reflow Phenomenon in the Catheterization Laboratory.
JACC Cardiovasc Interv. 2017 Feb 13;10(3):215-223. doi: 10.1016/j.jcin.2016.11.059.
7
Growth-differentiation factor-15 and major cardiac events.
Am J Med Sci. 2014 Apr;347(4):305-11. doi: 10.1097/MAJ.0b013e318291cd4e.
9
The multiple facets of the TGF-β family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1.
Cytokine Growth Factor Rev. 2013 Aug;24(4):373-84. doi: 10.1016/j.cytogfr.2013.05.003. Epub 2013 Jun 18.
10
Relation of growth-differentiation factor 15 to left ventricular remodeling in ST-segment elevation myocardial infarction.
Am J Cardiol. 2011 Oct 1;108(7):955-8. doi: 10.1016/j.amjcard.2011.05.028. Epub 2011 Jul 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验